Zivo Bioscience’s recent study with the University of Delaware demonstrates that their proprietary algal-based active ingredients can potentially reduce the transmission of Low Pathogenicity Avian Influenza (LPAI) in poultry. The study revealed a significant early decrease in viral titers in infected chickens treated with ZIVO’s ingredients and a significant delay in viral detection among healthy chickens exposed to infected birds that were treated with the ZIVO ingredients. This research focuses on preventing LPAI transmission, improving poultry health, and offering a potential alternative to traditional vaccines.
This news holds significant implications for the poultry industry, which constantly grapples with the economic and animal welfare challenges posed by avian influenza outbreaks. Current preventative measures, primarily vaccines, often fall short due to evolving viral strains and logistical complexities. ZIVO’s approach offers a potential solution by focusing on boosting the chickens’ immune response and reducing viral shedding, thereby limiting the spread of the virus, even in challenging real-world scenarios. This could lead to healthier flocks, reduced economic losses for producers, and a safer, more sustainable poultry supply chain.
The study evaluated the efficacy of ZIVO’s proprietary active ingredients, previously shown effective against coccidiosis, in a two-part controlled trial. The first part showed a significant early reduction in viral load in treated, infected chickens. The second part, mimicking real-world transmission, demonstrated a significant delay in viral detection in treated healthy chickens cohabitating with infected birds. While multiple product configurations were tested with varying efficacies, the results suggest that an optimized product could provide comprehensive LPAI protection. These findings support further research into ZIVO’s pipeline for broader viral challenges facing the industry.
This research paves the way for a potential paradigm shift in avian influenza management. Further studies are needed to refine product formulations, explore efficacy against other viral strains, and evaluate large-scale application in commercial settings. If successful, ZIVO’s technology could provide poultry producers with a valuable tool to proactively manage disease, improve animal welfare, and enhance the overall sustainability and security of the global poultry supply.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
